The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Kawakami, Hisato, Okamoto, Isamu, Yonesaka, Kimio, Okamoto, Kunio, Shibata, Kiyoko, Shinkai, Yume, Sakamoto, Haruka, Kitano, Michiko, Tamura, Takao, Nishio, Kazuto, Nakagawa, Kazuhiko
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2014
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323007/
https://ncbi.nlm.nih.gov/pubmed/25474137
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge